Literature DB >> 24370901

Association between atopy and herpetic eye disease: results from the pacific ocular inflammation study.

Durga S Borkar1, John A Gonzales1, Vivien M Tham2, Elizabeth Esterberg1, Aleli C Vinoya3, John V Parker3, Aileen Uchida3, Nisha R Acharya4.   

Abstract

IMPORTANCE: Immune dysregulation in patients with atopy has been hypothesized to increase susceptibility to viral infections. Herpetic eye disease (due to herpes simplex and herpes zoster) is a significant cause of visual impairment, and data on an association between this sight-threatening disease and atopy are limited.
OBJECTIVE: To assess the association between atopy and herpetic eye disease, including herpes simplex virus (HSV) ocular disease and herpes zoster ophthalmicus (HZO). DESIGN, SETTING, AND PARTICIPANTS: Retrospective, population-based case-control study from January 1, 2006, through December 31, 2007, at Kaiser Permanente Hawaii, a multispecialty managed care organization serving approximately 15% of the general Hawaiian population. Participants were 217,061 patients enrolled in the Kaiser Permanente Hawaii health plan during the study period. MAIN OUTCOMES AND MEASURES: Clinical diagnosis of HSV ocular disease or HZO during the study period determined by an initial search of the electronic medical record of Kaiser Permanente Hawaii and then confirmed through individual medical record review by a uveitis and cornea fellowship-trained ophthalmologist. Atopic disease status was determined based on International Classification of Diseases, Ninth Revision codes for patients with HSV ocular disease or HZO and 2 control groups, each randomly selected at a 4:1 ratio of controls to cases.
RESULTS: One hundred fourteen patients with HSV ocular disease and 137 patients with HZO were identified. Using the age- and sex-matched controls, patients who had atopy had a 2.6-fold (95% CI, 1.6-4.2; P < .001) higher odds of having HSV ocular disease compared with patients who did not have atopy. Similarly, patients with atopy had a 1.8-fold (95% CI, 1.2-2.8; P = .01) increased odds of having HZO. Patients with 2 or more atopic conditions had an 8.9-fold (95% CI, 3.5-22.6; P < .001) higher odds of having HSV ocular disease and a 2.9-fold (95% CI, 1.1-7.7; P = .04) higher odds of having HZO.
CONCLUSIONS: AND RELEVANCE The association between atopy and herpetic eye disease may be explained by various factors, including immunologic dysfunction in patients with atopy. Clinically, these results could help support the diagnosis of herpetic eye disease in these patients.

Entities:  

Mesh:

Year:  2014        PMID: 24370901     DOI: 10.1001/jamaophthalmol.2013.6277

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  5 in total

Review 1.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

2.  Asthma as a risk factor for zoster in adults: A population-based case-control study.

Authors:  Hyo Jin Kwon; Duk Won Bang; Eun Na Kim; Chung-Il Wi; Barbara P Yawn; Peter C Wollan; Brian D Lahr; Euijung Ryu; Young J Juhn
Journal:  J Allergy Clin Immunol       Date:  2015-12-28       Impact factor: 10.793

3.  [Corneal alterations in eyelid diseases].

Authors:  Elisabeth M Messmer
Journal:  Ophthalmologe       Date:  2020-09       Impact factor: 1.059

4.  Petri Net computational modelling of Langerhans cell Interferon Regulatory Factor Network predicts their role in T cell activation.

Authors:  Marta E Polak; Chuin Ying Ung; Joanna Masapust; Tom C Freeman; Michael R Ardern-Jones
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

5.  Text-Based Identification of Herpes Zoster Ophthalmicus With Ocular Involvement in the Electronic Health Record: A Population-Based Study.

Authors:  Chengyi Zheng; Lina S Sy; Hilary Tanenbaum; Yun Tian; Yi Luo; Bradley Ackerson; Hung Fu Tseng
Journal:  Open Forum Infect Dis       Date:  2021-01-03       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.